675 related articles for article (PubMed ID: 33622705)
1. Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance.
Galbo PM; Zang X; Zheng D
Clin Cancer Res; 2021 May; 27(9):2636-2647. PubMed ID: 33622705
[TBL] [Abstract][Full Text] [Related]
2. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer.
Zou R; Jiang Q; Jin T; Chen M; Yao L; Ding H
Front Immunol; 2022; 13():956224. PubMed ID: 36032075
[TBL] [Abstract][Full Text] [Related]
3. The molecular classification of cancer-associated fibroblasts on a pan-cancer single-cell transcriptional atlas.
Chen B; Chan WN; Xie F; Mui CW; Liu X; Cheung AHK; Lung RWM; Chow C; Zhang Z; Fang C; Yu P; Shi S; Zhou S; Chen G; Wang Z; Wang S; Ding X; Huang B; Liang L; Dong Y; Wong CC; Wu WKK; Cheng ASL; Wong N; Yu J; Lo KW; Tse GMK; Kang W; To KF
Clin Transl Med; 2023 Dec; 13(12):e1516. PubMed ID: 38148640
[TBL] [Abstract][Full Text] [Related]
4. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
[TBL] [Abstract][Full Text] [Related]
5. Broadening Drug Design and Targets to Tumor Microenvironment? Cancer-Associated Fibroblast Marker Expression in Cancers and Relevance for Survival Outcomes.
Dzobo K; Dandara C
OMICS; 2020 Jun; 24(6):340-351. PubMed ID: 32496971
[TBL] [Abstract][Full Text] [Related]
6. Single cell and bulk RNA sequencing identifies tumor microenvironment subtypes and chemoresistance-related IGF1
Jia X; Li Z; Zhou R; Feng W; Yi L; Zhang H; Chen B; Li Q; Huang S; Zhu X
Biochim Biophys Acta Mol Basis Dis; 2024 Apr; 1870(4):167123. PubMed ID: 38484940
[TBL] [Abstract][Full Text] [Related]
7. Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance.
Dzobo K; Dandara C
OMICS; 2020 Jun; 24(6):314-339. PubMed ID: 32496970
[TBL] [Abstract][Full Text] [Related]
8. Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC.
Wang S; Fan G; Li L; He Y; Lou N; Xie T; Dai L; Gao R; Yang M; Shi Y; Han X
Cancer Immunol Immunother; 2023 Jul; 72(7):2423-2442. PubMed ID: 37010552
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives.
Mao X; Xu J; Wang W; Liang C; Hua J; Liu J; Zhang B; Meng Q; Yu X; Shi S
Mol Cancer; 2021 Oct; 20(1):131. PubMed ID: 34635121
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analyses of the cancer-associated fibroblast subtypes and their score system for prediction of outcomes and immunosuppressive microenvironment in prostate cancer.
Gao Z; Zhang N; An B; Li D; Fang Z; Xu D
Cancer Cell Int; 2024 Apr; 24(1):127. PubMed ID: 38580966
[TBL] [Abstract][Full Text] [Related]
11. The cancer-associated fibroblast-related signature predicts prognosis and indicates immune microenvironment infiltration in gastric cancer.
Mak TK; Li X; Huang H; Wu K; Huang Z; He Y; Zhang C
Front Immunol; 2022; 13():951214. PubMed ID: 35967313
[TBL] [Abstract][Full Text] [Related]
12. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer.
Chen H; Yao J; Bao R; Dong Y; Zhang T; Du Y; Wang G; Ni D; Xun Z; Niu X; Ye Y; Li HB
Mol Cancer; 2021 Feb; 20(1):29. PubMed ID: 33557837
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages.
Takahashi H; Sakakura K; Kudo T; Toyoda M; Kaira K; Oyama T; Chikamatsu K
Oncotarget; 2017 Jan; 8(5):8633-8647. PubMed ID: 28052009
[TBL] [Abstract][Full Text] [Related]
14. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15
Dominguez CX; Müller S; Keerthivasan S; Koeppen H; Hung J; Gierke S; Breart B; Foreman O; Bainbridge TW; Castiglioni A; Senbabaoglu Y; Modrusan Z; Liang Y; Junttila MR; Klijn C; Bourgon R; Turley SJ
Cancer Discov; 2020 Feb; 10(2):232-253. PubMed ID: 31699795
[TBL] [Abstract][Full Text] [Related]
15. Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities.
Caramelo B; Zagorac S; Corral S; Marqués M; Real FX
Eur Urol Oncol; 2023 Aug; 6(4):366-375. PubMed ID: 36890105
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Cancer-Associated Fibroblast-Related Gene Signatures in Hepatocellular Carcinoma.
Dong W; Xie Y; Huang H
Front Endocrinol (Lausanne); 2022; 13():884777. PubMed ID: 35733776
[TBL] [Abstract][Full Text] [Related]
17. Transcription factors in fibroblast plasticity and CAF heterogeneity.
Melchionna R; Trono P; Di Carlo A; Di Modugno F; Nisticò P
J Exp Clin Cancer Res; 2023 Dec; 42(1):347. PubMed ID: 38124183
[TBL] [Abstract][Full Text] [Related]
18. Cancer-Associated Fibroblast Heterogeneity in Malignancy with Focus on Oral Squamous Cell Carcinoma.
Arebro J; Lee CM; Bennewith KL; Garnis C
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279300
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive multi-omics analysis identifies a robust scoring system for cancer-associated fibroblasts and intervention targets in colorectal cancer.
Wang F; Li Z; Xu T; Zhang Q; Ma T; Li S; Wang X
J Cancer Res Clin Oncol; 2024 Mar; 150(3):124. PubMed ID: 38478111
[TBL] [Abstract][Full Text] [Related]
20. miRNAs Delivery for Cancer-associated Fibroblasts' Activation and Drug Resistance in Cancer Microenvironment.
Anajafi S; Paryan M; Khoshnazar A; Soleimani M; Mohammadi-Yeganeh S
Endocr Metab Immune Disord Drug Targets; 2024; 24(3):333-347. PubMed ID: 37612874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
